Trial Profile
A Randomized, Double Blind, Placebo-controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Fixed-dose Combination RHB-104 in Subjects With Moderately to Severely Active Crohn's Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Clarithromycin/clofazimine/rifabutin (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Acronyms MAP-US; MAPUS
- Sponsors RedHill Biopharma
- 29 Dec 2019 Status changed from active, no longer recruiting to completed.
- 28 Oct 2019 According to a RedHill Biopharma media release, data form this trial will be presented will be presented at the American College of Gastroenterology (ACG) 2019 Annual Scientific Meeting, being held October 25-30, in San Antonio, Texas.
- 11 Oct 2019 According to a RedHill Biopharma media release, intends to meet with the FDA again in the coming months to discuss the RHB-104 program, including data from this trial.